Peters M, Solem F, Goldschmidt J, Schirmacher P, Rose-John S
I. Department of Medicine, Section of Pathophysiology, University of Mainz, Mainz, Germany.
Exp Hematol. 2001 Feb;29(2):146-55. doi: 10.1016/s0301-472x(00)00650-0.
We recently established transgenic animals expressing either interleukin-6 (IL-6) or the soluble IL-6 receptor (sIL-6R) alone, or both components, IL-6 and the sIL-6R, in the liver. This animal model demonstrated that the expression of IL-6 in combination with its sIL-6R led to extramedullary expansion of hematopoietic progenitor cells in the spleen and liver.
We studied other relevant hematopoietic cytokines involved in the IL-6/sIL-6R-induced stimulation of hematopoiesis.
Using immunohistochemistry, we showed that cell-associated stem cell factor (SCF) and Flt-3L expression were upregulated in liver and spleen only in double transgenic mice but not in IL-6 or sIL-6R single transgenic animals. Moreover, on murine NIH/3T3 fibroblasts and on human primary forskin fibroblasts, stimulation with the IL-6/sIL-6R complex, and to a lesser extent with IL-6 alone, led to induction of cellular SCF and Flt-3L expression. When human HTB-158 fibroblasts were stimulated with the IL-6/sIL-6R complex and subsequently cocultured with human umbilical cord CD34(+) cells, a significant upregulation in colony growth was found.
We showed that IL-6 in combination with its soluble receptor stimulates cellular SCF and Flt-3L expression in vivo and in vitro. Cellular upregulation of SCF and Flt-3L by IL-6/sIL-6R might be used for the development of new stroma cell systems for ex vivo expansion of hematopoietic progenitor cells.
我们最近构建了在肝脏中单独表达白细胞介素-6(IL-6)或可溶性IL-6受体(sIL-6R),或同时表达IL-6和sIL-6R这两种成分的转基因动物。该动物模型表明,IL-6与其sIL-6R联合表达会导致脾脏和肝脏中造血祖细胞的髓外扩增。
我们研究了参与IL-6/sIL-6R诱导造血刺激的其他相关造血细胞因子。
通过免疫组织化学,我们发现仅在双转基因小鼠的肝脏和脾脏中,细胞相关干细胞因子(SCF)和Flt-3L的表达上调,而在IL-6或sIL-6R单转基因动物中未上调。此外,用IL-6/sIL-6R复合物刺激小鼠NIH/3T3成纤维细胞和人原代包皮成纤维细胞时,会诱导细胞SCF和Flt-3L表达,单独用IL-6刺激时诱导作用较弱。当用人IL-6/sIL-6R复合物刺激人HTB-158成纤维细胞,随后与人类脐带血CD34(+)细胞共培养时,发现集落生长显著上调。
我们发现IL-6与其可溶性受体联合在体内和体外均可刺激细胞SCF和Flt-3L表达。IL-6/sIL-6R对SCF和Flt-3L的细胞上调作用可能用于开发新的基质细胞系统,用于造血祖细胞的体外扩增。